Atıf Formatları
miR-17 in imatinib resistance and response to tyrosine kinase inhibitors in chronic myeloid leukemia cells
  • IEEE
  • ACM
  • APA
  • Chicago
  • MLA
  • Harvard
  • BibTeX

B. Firatligil Et Al. , "miR-17 in imatinib resistance and response to tyrosine kinase inhibitors in chronic myeloid leukemia cells," JOURNAL OF BUON , vol.18, no.2, pp.437-441, 2013

Firatligil, B. Et Al. 2013. miR-17 in imatinib resistance and response to tyrosine kinase inhibitors in chronic myeloid leukemia cells. JOURNAL OF BUON , vol.18, no.2 , 437-441.

Firatligil, B., Avci, C. B., & Baran, Y., (2013). miR-17 in imatinib resistance and response to tyrosine kinase inhibitors in chronic myeloid leukemia cells. JOURNAL OF BUON , vol.18, no.2, 437-441.

Firatligil, YUSUF, C. Biray Avci, And Y. Baran. "miR-17 in imatinib resistance and response to tyrosine kinase inhibitors in chronic myeloid leukemia cells," JOURNAL OF BUON , vol.18, no.2, 437-441, 2013

Firatligil, YUSUF Et Al. "miR-17 in imatinib resistance and response to tyrosine kinase inhibitors in chronic myeloid leukemia cells." JOURNAL OF BUON , vol.18, no.2, pp.437-441, 2013

Firatligil, B. Avci, C. B. And Baran, Y. (2013) . "miR-17 in imatinib resistance and response to tyrosine kinase inhibitors in chronic myeloid leukemia cells." JOURNAL OF BUON , vol.18, no.2, pp.437-441.

@article{article, author={YUSUF BARAN Et Al. }, title={miR-17 in imatinib resistance and response to tyrosine kinase inhibitors in chronic myeloid leukemia cells}, journal={JOURNAL OF BUON}, year=2013, pages={437-441} }